| Literature DB >> 30847471 |
Siri L Rydning1,2, Jeanette Koht1,3, Ying Sheng4, Piotr Sowa5, Hanne S Hjorthaug4, Iselin M Wedding2, Anne Kjersti Erichsen6, Inger Anette Hovden7, Paul H Backe8,9, Chantal M E Tallaksen2, Magnus D Vigeland1,4, Kaja K Selmer10,11.
Abstract
Entities:
Mesh:
Substances:
Year: 2019 PMID: 30847471 PMCID: PMC6439323 DOI: 10.1093/brain/awz041
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Figure 1Pedigrees, MRIs and sequencing chromatograms. (A) Pedigrees of the 10 families showing co-segregation of the variants and disease. In Families F1–F6 in trans status was confirmed by mRNA analyses, and in Families F7-F10 by sequencing of family members. In Family 7, the parents were not available for analyses, hence adult children were sequenced and found to carry only one of the variants each (results not included in the pedigree due to anonymity restrictions). Asterisks indicate that whole exome sequencing was performed. (B) MRI of the brain. (i–iv) The superior cerebellar peduncles of Patient F2–1 showing hyperintense signal in FLAIR MRI in coronal (i), sagittal (ii) and axial (iii) views, and isointense signal in T1-weighted coronal images (iv). Arrows indicate the superior cerebellar peduncles. (v) Coronal T1-weighted image of Patient F7–1 showing mild atrophy of the cerebellar vermis (midline) and hemispheres. (vi) Axial FLAIR image of Patient F8–1 showing hyperintense signal in the corticospinal tracts at the level of the posterior limb of the internal capsule (arrows). The MRI signal in all images was assessed in relation to the reference area in the caudate nucleus (Vrij-van den Bos ). (C) Analysis of NMD of the c.3655G>T variant. Messenger RNA from lymphocytes cultured with and without inhibitor of NMD was reverse transcribed and amplified by PCR, followed by Sanger sequencing (details in the Supplementary material). The figure shows sequencing chromatograms of Patients F1–2 and F2–1. These patients carry the c.3655 G>T and c.1909+22G>A variants in trans, with the latter previously shown to result in a leaky splice site and partial NMD. The c.3655 position is marked by an arrow in the centre of each graph. [C(i and ii)] Chromatograms from analysis of Patient F1–2 without and with NMD inhibitor, respectively. [C(iii and iv)] Chromatograms from analysis of Patient F2–1 without and with NMD inhibitor, respectively. Notably, addition of NMD inhibitor led to increased amounts of product from the c.3655T allele as compared to the c.3655G allele. This result is consistent with complete NMD of the c.3655G>T variant, and partial degradation of transcripts from the c.1909+22G>A variant.
Clinical characteristics of the patients
| Patient ID | F1–1 | F1–2 | F2–1 | F3–1 | F4–1 | F4–2 | F5–1 | F6–1 | F7–1 | F7–2 | F8–1 | F9–1 | F10–1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variant 1 | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1909+22G>A | c.1771–6C>G |
| Variant 2 | c.3655G>T | c.3655G>T | c.3655G>T | c.3655G>T | c.3655G>T | c.3655G>T | c.3655G>T | c.3655G>T | c.1682G>A | c.1682G>A | c.1378_1380del | c.1378_1380del | c.1771–6C>G |
| Gender | M | F | M | M | F | M | M | F | M | M | M | F | M |
| Age at onset, y | 5 | 14 | 12 | 17 | 20 | 13 | 30 | 10 | 11 | 20 | 17 | 5 | 4 |
| Disease duration, y | 62 | 51 | 35 | 27 | 28 | 33 | 15 | 55 | 46 | 29 | 28 | 24 | 41 |
| SARA (0–40)/SPRS (0–52) | 29/34 | 24.5/25 | 28/33 | 22/22 | np | 17/18 | 7.5/11 | 27/21 | 17.5/28 | 11.5/18 | 16/23 | 5/np | np |
| LL spasticity/ reflexes | -/↓↓ | -/↓↓ | +/↓ | +/↓ | +/↓ | +/↓↓ | +/↓ | +/↓ | +/↓ | +/↑ | +/↓↓ | -/↓↓ | +/↓ |
| Extensor plantar responses | + | + | + | + | + | + | + | + | + | + | + | + | + |
| LL weakness/ atrophy | +/+ | +/+ | +/+ | +/+ | +/np | +/+ | +/+ | +/+ | +/+ | +/+ | +/+ | -/- | +/+ |
| Dysarthria | + | + | + | + | - | - | - | + | - | + | + | - | + |
| UL/LL ataxia | +/nt | +/+ | +/+ | +/+ | -/+ | +/+ | +/- | +/+ | -/+ | +/+ | +/+ | +/+ | +/+ |
| Postural tremor UL | + | + | + | + | - | - | - | + | - | - | + | - | + |
| Head and neck titubation/dystonia | +/- | +/- | +/- | +/+ | -/- | +/+ | -/- | +/+ | -/- | -/- | -/+ | +/+ | +/+ |
| LL vibration/surface sensation | ↓↓/↓ | ↓↓/↓ | ↓↓/↓ | N/N | ↓/↓ | ↓/N | ↓↓/↓ | ↓↓/N | ↓↓/↓ | ↓↓/N | ↓↓/↓↓ | ↓/N | ↓↓/N |
| Urinary urgency | + | + | + | - | + | - | + | - | + | + | + | - | - |
| Dental abnormalities | + | + | + | + | np | + | - | + | + | + | + | + | + |
| Myopia | - | - | + | - | np | - | - | + | + | - | + | + | - |
| Hypogonadism | np | - | - | - | np | - | - | - | - | - | + | np | - |
| Polyneuropathy | np | - | nt | - | np | + | - | - | + | - | - | - | - |
| Abnormal SEP/BAEP/VEP | np | +/-/- | -/+/- | +/+/- | np | nt/+/nt | np | nt/nt/- | +/+/- | +/+/- | +/+/- | -/np/- | np |
| SCP hyperintensity (FLAIR) | np | + | + | + | np | + | + | nt | + | + | + | + | + |
| Thin cervical spinal cord | np | + | + | + | np | + | + | nt | + | + | + | + | + |
| Thinning of corpus callosum | np | - | - | - | np | - | - | nt | - | - | - | - | - |
| Total white matter score | np | 3 | 6 | 6 | np | nt | 2 | nt | 3 | 5 | 6 | 1 | 1 |
| Total atrophy score | np | 2 | 3 | 1 | np | 3 | 2 | 2 | 2 | 0 | 3 | 3 | 3 |
+ = present; - = absent; ↑ = increased; ↓ = reduced; ↓↓ = absent; LL = lower limbs; N = normal; np = not performed/not available; nt = not testable due to tremor/other co-morbidity; SARA = Scale for Assessment and Rating of Ataxia (Schmitz-Hubsch ); SCP = superior cerebellar peduncles; SEP/BAEP/VEP = somatosensory/brain stem auditory/visual evoked potentials; SNAP = sensory nerve action potentials; SPRS = Spastic Paraplegia Rating Scale (Schule ); UL = upper limbs.
aFollowing the 4H Leukodystrophy Brain MRI Scoring System. Total white matter score = 0–44; Total atrophy score = 0–10 (Vrij-van den Bos ).